-
Daiichi Sankyo2020-08-03 09:35:39Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
-
Daiichi Sankyo2019-02-05 10:30:35FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for
-
Daiichi Sankyo2019-01-14 12:00:01Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low
-
Daiichi Sankyo2020-08-03 09:36:09Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the